Krystal Biotech (NASDAQ:KRYS) subsidiary Jeune Aesthetics reported promising phase 1 interim efficacy and safety results for KB301, its candidate for wrinkles and lines.

The drug is designed to deliver the COL3A1 transgene and increase type III collagen levels in the skin. The phase 1 study results are from two cohorts, one in lateral canthal lines and the other in dynamic wrinkles of the décolleté.

Steve Yoelin, a principal trial investigator, said that current injectable aesthetic meds manipulate rather than rejuvenate skin. He added that KB301 can replenish skin and delay signs of aging.

Results showed that after two months of treatment, 75% of subjects in the canthal lines group had at least a one point improvement and 50% had a two point improvement on the Global Aesthetic Improvement Scale.

In the wrinkles cohort, after two months, 94% of patients had at least a one point improvement and 28% had a two point improvement.

Jeune noted that the décolleté wrinkles indication was chosen to advance to a phase 2 study in 2025.